Anton Cheltsov holds an M.S. in Chemistry from Moscow State University in Russia and a Ph.D. in Medical Sciences from the University of South Florida, College of Medicine. He is the founder of Q-MOL LLC and the developer of Q-MOL’s high fidelity protein-ligand docking technology. Dr. Cheltsov has an extensive background in computational biology and in silico drug discovery that he developed during postdoctoral training at The Scripps Research Institute. Shortly after, he continued these studies at the Prebys Chemical Genomics Center at the Sanford-Burnham-Prebys Discovery Institute. There he was a member of the cheminformatics and high content analysis group within high throughput screening team. Dr. Cheltsov is currently engaged in several drug discovery collaboration projects with premier academic research institutions such as The Scripps Research Institute (where he is an Adjunct Professor), The Sanford-Burnham-Prebys Discovery Institute and Duke University. Dr. Cheltsov carried out the in silico screens of chemical compounds that provided the core of Xtem’s technology.
Dr. Anton Cheltsov, Ph.D.